Publications: Stephen Ezell

The Trump administration’s Section 232 pharmaceutical tariffs will needlessly raise drug costs, harm U.S. patients, and undermine both domestic manufacturing and global biopharmaceutical innovation, while better policy options exist to strengthen the industry without these damaging side effects.

Boosting U.S. competitiveness in national power industries is necessary, but not sufficient to avoid losing to China. America also must take measures to slow the PRC’s progress toward global dominance. This report provides more than 100 actionable recommendations for the administration and Congress. Western allies should take many of the same steps.

To win the techno-economic competition with China, America must be able to assess the factors impacting the global competitiveness of its advanced-technology industries. Using the auto industry as a template, U.S. competitiveness has faltered considerably.

CFIUS’ procedures need to be strengthened to ensure that Chinese entities, particularly those influenced or backed by Chinese government influence or funding, cannot acquire U.S. companies or technology that could harm America’s economic or national security.

Europe once led the world in biopharmaceutical innovation, but it lost ground after adopting policies that weakened incentives for R&D and innovation. America must learn from Europe’s experience to preserve its own biopharma leadership and the related economic benefits and access to the most innovative drugs.

The United States should use MC14 to push for a WTO that actively promotes fair market competition—not one that passively accepts non-market policies, overcapacity, and coercive distortions that are undermining the global trading system.

The international reference pricing-based GUARD model lacks a sound premise for its rationale, is fundamentally flawed in its design, and should be withdrawn in full by CMS.

The international reference pricing-based GLOBE model lacks a sound premise for its rationale, is fundamentally flawed in its design, and should be withdrawn in full by CMS.

Europe has long free-ridden on U.S. drug innovation—and while President Trump is right to push allies to pay their fair share, importing Europe’s price controls into the U.S. would undercut the very innovation the world depends on.

If the year ahead in technology and innovation policy lives up to its potential, it could be a consequential one because there is a long list of important issues on the table. Herein, we offer 10 that are on top of our minds.